Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira A Jacobs

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancer Treatment Reviews|March 27, 2019
Emerging therapeutic targets for patients with advanced prostate cancerFred Saad, Neal Shore, Tian Zhang, et al.
Cancer Biology & Therapy|January 11, 2021
Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced diseaseRebecca C Arend, Amy Jackson-Fisher, Ira A Jacobs, et al.
Future Oncology (London, England)|June 12, 2024
Current and anticipated future state of cachexia care in patients with cancerAaron H Chevinsky, John Goodman, Jackie Risco, et al.
Journal of Cachexia, Sarcopenia and Muscle|June 29, 2026
Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature ReviewJeffrey Crawford, Marie Fallon, Jarjieh Fang, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 2, 2020
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature ReviewsLauren J Lee, Christina S Kwon, Anna Forsythe, et al.
Paediatric Drugs|June 26, 2021
Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion RecommendationsElly Barry, Jaimie A Walsh, Scott L Weinrich, et al.
Journal for Immunotherapy of Cancer|April 18, 2019
Immunogenicity of immunomodulatory, antibody-based, oncology therapeuticsJasmine Davda, Paul Declerck, Siwen Hu-Lieskovan, et al.
Drug Discovery Today|April 28, 2015
Key considerations in the preclinical development of biosimilarsLynne A Bui, Susan Hurst, Gregory L Finch, et al.
Targeted Oncology|October 25, 2021
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of AdministrationSiwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Mabs|April 7, 2016
Evaluating imbalances of adverse events during biosimilar developmentAlicia M Vana, Amy W Freyman, Steven D Reich, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Treatment Reviews|March 27, 2019
Emerging therapeutic targets for patients with advanced prostate cancerFred Saad, Neal Shore, Tian Zhang, et al.
Cancer Biology & Therapy|January 11, 2021
Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced diseaseRebecca C Arend, Amy Jackson-Fisher, Ira A Jacobs, et al.
Future Oncology (London, England)|June 12, 2024
Current and anticipated future state of cachexia care in patients with cancerAaron H Chevinsky, John Goodman, Jackie Risco, et al.
Journal of Cachexia, Sarcopenia and Muscle|June 29, 2026
Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature ReviewJeffrey Crawford, Marie Fallon, Jarjieh Fang, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 2, 2020
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature ReviewsLauren J Lee, Christina S Kwon, Anna Forsythe, et al.
Paediatric Drugs|June 26, 2021
Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion RecommendationsElly Barry, Jaimie A Walsh, Scott L Weinrich, et al.
Journal for Immunotherapy of Cancer|April 18, 2019
Immunogenicity of immunomodulatory, antibody-based, oncology therapeuticsJasmine Davda, Paul Declerck, Siwen Hu-Lieskovan, et al.
Drug Discovery Today|April 28, 2015
Key considerations in the preclinical development of biosimilarsLynne A Bui, Susan Hurst, Gregory L Finch, et al.
Targeted Oncology|October 25, 2021
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of AdministrationSiwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Mabs|April 7, 2016
Evaluating imbalances of adverse events during biosimilar developmentAlicia M Vana, Amy W Freyman, Steven D Reich, et al.
Pageof 4